DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Financial Counselors Inc.

Financial Counselors Inc. lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 89.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,962 shares of the medical device company’s stock after selling 32,139 shares during the period. Financial Counselors Inc.’s holdings in DexCom were worth $492,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Centaurus Financial Inc. raised its position in shares of DexCom by 5.5% during the 1st quarter. Centaurus Financial Inc. now owns 1,236 shares of the medical device company’s stock worth $632,000 after acquiring an additional 64 shares in the last quarter. Stableford Capital II LLC raised its position in shares of DexCom by 2.1% during the 4th quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock worth $563,000 after acquiring an additional 88 shares in the last quarter. Fortis Capital Advisors LLC raised its position in shares of DexCom by 5.5% during the 2nd quarter. Fortis Capital Advisors LLC now owns 1,744 shares of the medical device company’s stock worth $224,000 after acquiring an additional 91 shares in the last quarter. Ascent Group LLC grew its stake in DexCom by 2.1% during the 3rd quarter. Ascent Group LLC now owns 4,778 shares of the medical device company’s stock worth $577,000 after buying an additional 98 shares during the last quarter. Finally, Jaffetilchin Investment Partners LLC grew its stake in DexCom by 7.7% during the 1st quarter. Jaffetilchin Investment Partners LLC now owns 1,412 shares of the medical device company’s stock worth $440,000 after buying an additional 101 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Buying and Selling

In related news, CEO Kevin R. Sayer sold 37,325 shares of DexCom stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $123.63, for a total transaction of $4,614,489.75. Following the completion of the transaction, the chief executive officer now directly owns 362,841 shares of the company’s stock, valued at $44,858,032.83. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CEO Kevin R. Sayer sold 37,325 shares of DexCom stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $123.63, for a total transaction of $4,614,489.75. Following the completion of the transaction, the chief executive officer now directly owns 362,841 shares of the company’s stock, valued at $44,858,032.83. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Jereme M. Sylvain sold 2,734 shares of DexCom stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $123.63, for a total value of $338,004.42. Following the transaction, the chief financial officer now directly owns 74,505 shares of the company’s stock, valued at $9,211,053.15. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 235,892 shares of company stock valued at $31,252,330. 0.41% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on DXCM. StockNews.com upgraded DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Piper Sandler raised their price target on DexCom from $135.00 to $150.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 19th. UBS Group raised their price target on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday. Royal Bank of Canada started coverage on DexCom in a research note on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target on the stock. Finally, Citigroup lifted their target price on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Two equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $141.40.

DexCom Stock Down 2.5 %

DXCM opened at $136.14 on Friday. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48. The business has a 50 day simple moving average of $128.56 and a 200-day simple moving average of $115.41. The stock has a market capitalization of $52.48 billion, a P/E ratio of 103.92, a P/E/G ratio of 2.40 and a beta of 1.20. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.43 by $0.07. The business had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.02 billion. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The company’s quarterly revenue was up 26.9% compared to the same quarter last year. During the same period last year, the firm earned $0.34 EPS. On average, equities analysts anticipate that DexCom, Inc. will post 1.76 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.